CLINICAL STUDY TO COMPARE THE EFFICACY AND TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF TRASTUZUMAB BIOSIMILAR HLX02 AND EU-SOURCED HERCEPTIN® IN HER2-POSITIVE, LOCALLY RECURRENT OR PREVIOUSLY UNTREATED METASTATIC BREAST CANCER: